triple negative breast cancer

[Advanced Healthcare Materials] Researchers used a recently developed composite hydrogel composed of a fibrin matrix and phase-shift emulsion, termed an acoustically-responsive scaffold, to investigate effects of local mechanical properties on breast cancer cell signaling.

[Oncogene] Scientists revealed that Hippo signaling effector YAP1 functioned as a key downstream regulator of LIN28 to modulate the CSC-like properties and tumor progressions in triple negative breast cancer.

[Nanoscale] The authors characterized the effects of iron(II)-based complexes on the structural and morphological properties of epithelial non-tumorigenic and tumorigenic breast cell lines using atomic force microscopy, flow cytometry and immunofluorescence microscopy.

[Drug Discovery Today] The authors describe ongoing clinical trials on druggable targets in TNBC-brain metastasis (BM) for a more targeted treatment and introduce the obstacles hindering drug delivery to the brain, bringing strategies and advancing knowledge for future steps in the treatment of patients with TNBC-BM.

[Akeso, Inc. (PR Newswire, Inc.)] Akeso, Inc. announced that Ligufalimab and Ivonescimab have obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate a Phase II clinical trial with chemotherapy as first-line therapy for unresectable locally advanced or metastatic triple negative breast cancer.

[Cancer Gene Therapy] Scientists investigated the potential involvement of CLK4 in the metastasis and progression of mesenchymal-like (MES-) TNBC. In the MES-TNBC cell lines, the CLK4 expression was elevated.